- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00527735
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
2018. június 18. frissítette: Bristol-Myers Squibb
A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
A tanulmány áttekintése
Állapot
Befejezve
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
334
Fázis
- 2. fázis
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
Alabama
-
Birmingham, Alabama, Egyesült Államok, 35235
- Birmingham Hematology & Oncology Assoc. Llc
-
-
Arizona
-
Scottsdale, Arizona, Egyesült Államok, 85259
- Mayo Clinic
-
Tucson, Arizona, Egyesült Államok, 85715
- Acrc/Arizona Clinical Research Center, Inc.
-
-
California
-
Corona, California, Egyesült Államok, 92879
- Compassionate Cancer Care Medical Group
-
Fountain Valley, California, Egyesült Államok, 92708
- Compassionate Cancer Care Medical Group, Inc.
-
Los Angeles, California, Egyesült Államok, 90025
- The Angeles Clinic & Research Institute, Inc
-
Montebello, California, Egyesült Államok, 90640
- Oncology Care Medical Associates
-
Riverside, California, Egyesült Államok, 92501
- Compassionate Cancer Care Medical Group
-
San Diego, California, Egyesült Államok, 92123
- Sharp Clinical Oncology Research
-
-
Florida
-
Orlando, Florida, Egyesült Államok, 32806
- M D Anderson Cancer Center- Orlando
-
-
Georgia
-
Atlanta, Georgia, Egyesült Államok, 30341
- Georgia Cancer Specialists
-
-
Illinois
-
Chicago, Illinois, Egyesült Államok, 60637
- University of Chicago Medical Center
-
Park Ridge, Illinois, Egyesült Államok, 60068
- Local Institution
-
-
Kentucky
-
Hazard, Kentucky, Egyesült Államok, 41701
- Kentucky Cancer Clinic
-
-
Maryland
-
Hagerstown, Maryland, Egyesült Államok, 21740
- The John R. Marsh Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Egyesült Államok, 55455
- The Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Egyesült Államok, 89135
- Nevada Cancer Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, Egyesült Államok, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New York
-
New York, New York, Egyesült Államok, 10017
- Local Institution
-
-
North Carolina
-
Concord, North Carolina, Egyesült Államok, 28025
- Cmc-Northeast/ Northeast Oncology Associates
-
-
Ohio
-
Canton, Ohio, Egyesült Államok, 44718
- Gabrail Cancer Center
-
Columbus, Ohio, Egyesült Államok, 43235
- Hematology Oncology Consultants, Inc
-
-
Pennsylvania
-
Langhorne, Pennsylvania, Egyesült Államok, 19047
- St. Mary Medical Center
-
Sayre, Pennsylvania, Egyesült Államok, 18840
- Guthrie Clinical Research
-
-
South Carolina
-
Sumter, South Carolina, Egyesült Államok, 29150
- Santee Hematology/Oncology
-
-
Texas
-
Lubbock, Texas, Egyesült Államok, 79415
- Southwest Cancer Treatment And Research Center
-
-
-
-
-
Belfort, Franciaország, 90016
- Local Institution
-
Caen, Franciaország, 14076
- Local Institution
-
Marseille Cedex 9, Franciaország, 13274
- Local Institution
-
Rennes Cedex 9, Franciaország, 35033
- Local Institution
-
-
-
-
-
Vellore, India, 632004
- Local Institution
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, India, 500082
- Local Institution
-
-
Gujarat
-
Navrangpura, Ahmedabad, Gujarat, India, 380009
- Local Institution
-
-
Karnataka
-
Manipal, Karnataka, India, 576104
- Local Institution
-
-
Kerala
-
Trivandrum, Kerala, India, 695011
- Local Institution
-
-
-
-
-
Gdansk, Lengyelország, 80-952
- Local Institution
-
Krakow, Lengyelország, 31-826
- Local Institution
-
Olsztyn, Lengyelország, 10-513
- Local Institution
-
Szczecin, Lengyelország, 70-891
- Local Institution
-
-
-
-
-
Bochum, Németország, 44791
- Local Institution
-
Coswig, Németország, 01640
- Local Institution
-
Ebensfeld, Németország, 96250
- Local Institution
-
Grosshansdorf, Németország, 22927
- Local Institution
-
Halle (Saale), Németország, 06120
- Local Institution
-
Hamburg, Németország, 21075
- Local Institution
-
Koeln, Németország, 51109
- Local Institution
-
Leipzig, Németország, 04103
- Local Institution
-
Mainz, Németország, 55131
- Local Institution
-
Muenchen, Németország, 81675
- Local Institution
-
-
-
-
-
Genova, Olaszország, 16132
- Local Institution
-
Siena, Olaszország, 53100
- Local Institution
-
Torino, Olaszország, 10143
- Local Institution
-
-
-
-
-
Arkhangelsk, Orosz Föderáció, 163045
- Local Institution
-
Chelyabinsk, Orosz Föderáció, 454087
- Local Institution
-
Ivanovo, Orosz Föderáció, 153013
- Local Institution
-
Moscow, Orosz Föderáció, 115478
- Local Institution
-
Moscow, Orosz Föderáció, 105077
- Local Institution
-
Moscow, Orosz Föderáció, 125284
- Local Institution
-
Pyatigorsk, Orosz Föderáció, 357502
- Local Institution
-
Saint-Petersburg, Orosz Föderáció, 190005
- Local Institution
-
Sochi, Orosz Föderáció, 354057
- Local Institution
-
St. Petersburg, Orosz Föderáció, 197022
- Local Institution
-
St. Petersburg, Orosz Föderáció, 198255
- Local Institution
-
St. Petersburg, Orosz Föderáció, 194044
- Local Institution
-
St. Petersburg, Orosz Föderáció, 194291
- Local Institution
-
-
-
-
-
Dnipropetrovsk, Ukrajna, 49102
- Local Institution
-
Donetsk, Ukrajna, 83092
- Local Institution
-
Kharkov, Ukrajna, 46023
- Local Institution
-
Lviv, Ukrajna, 79031
- Local Institution
-
Ternopol, Ukrajna, 46023
- Local Institution
-
Uzhgorod, Ukrajna, 88014
- Local Institution
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
18 év és régebbi (Felnőtt, Idősebb felnőtt)
Egészséges önkénteseket fogad
Nem
Tanulmányozható nemek
Összes
Leírás
Inclusion Criteria:
- Histologically or cytologically confirmed lung cancer (Stage IIIb/IV nonsmall-cell lung cancer or extensive stage small-cell lung cancer [SCLC])
- Measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified World Health Organization criteria
- Eastern Cooperative Oncology Group performance status of ≤1 at study entry
- Accessible for treatment and follow-up
Exclusion Criteria:
- Brain metastases
- Malignant pleural effusion
- Autoimmune disease
- Motor neuropathy of autoimmune origin
- SCLC-related paraneoplastic syndromes
- Any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)
Prior systemic therapy for lung cancer. Prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.
- Grade 2 peripheral neuropathy (motor or sensory)
- Known HIV or hepatitis B or C infection
- Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). However, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.
- Inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dL.
- Inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (ULN), or ≥2.5 times the ULN if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the ULN or ≥5 times the ULN if liver metastases are present.
- Inadequate renal function defined by a serum creatinine level ≥2.5 times the ULN
- Inadequate creatinine clearance defined as less than 50 mL/min.
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)
|
Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses).
Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction.
Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses).
Dose modifications (reductions as well as delays) done as per product label.
Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization.
Dose modifications (reductions as well as delays) done as per product label.
|
Kísérleti: Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)
|
Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses).
Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction.
Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses).
Dose modifications (reductions as well as delays) done as per product label.
Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization.
Dose modifications (reductions as well as delays) done as per product label.
|
Aktív összehasonlító: Ipilimumab placebo + paclitaxel + carboplatin
|
Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction.
Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses).
Dose modifications (reductions as well as delays) done as per product label.
Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization.
Dose modifications (reductions as well as delays) done as per product label.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC)
Időkeret: Tumor assessed at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance until immune-related Progressive Disease (irPD) or death (of censored, maximum reached: 16.5 months)
|
irPFS is defined as the time between the randomization date and date of immune-related Progressive Disease (irPD) (at least 25% increase percentage change in total tumor burden, including new lesions) or death, whichever occurs first.
For patients with no recorded postbaseline tumor assessments, irPFS is censored at randomization.
Participant who die without reported irPD are considered to have progressed on the date of death.
For those who remain alive and have no irPD, irPFS is censored on the date of last evaluable tumor assessment.
Independent review committee performed tumor assessment.
|
Tumor assessed at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance until immune-related Progressive Disease (irPD) or death (of censored, maximum reached: 16.5 months)
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Progression-free Survival (PFS) in Participants With NSCLC Per Modified World Health Organization (mWHO) Criteria
Időkeret: Randomization date to date of progression or death (of censored, maximum reached: 13.6 months)
|
By mWHO criteria, PFS is defined as the time between the randomization date and the date of progression or death, whichever occurs first.
For participants with no recorded postbaseline tumor assessment, PFS was censored at the day of randomization.
A participant who died without reported prior progression was considered to have progressed on the date of death.
For those who remain alive and have not progressed, PFS was censored on the date of last evaluable tumor assessment.
Independent review committee performed tumor assessment.
|
Randomization date to date of progression or death (of censored, maximum reached: 13.6 months)
|
Overall Survival in Participants With NSCLC
Időkeret: Randomization date to date of death (of censored, maximum reached: 26.5 months)
|
Overall Survival is defined as the time from the date of randomization until the date of death.
For participants who have not died, Overall Survival was censored at the recorded last date of contact; participants with a missing recorded last date of contact were censored at the last date the participant was known to be alive.
|
Randomization date to date of death (of censored, maximum reached: 26.5 months)
|
Best Overall Response Rate (BORR) Per mWHO Criteria in Participants With NSCLC and SCLC
Időkeret: Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance
|
mWHO criteria define BORR as the number of patients with best overall response of Complete Response (CR) or Partial Response (PR), divided by the total number of participants in the data set (multiplied by 100 for percentage).
CR=Complete disappearance of all index lesions; PR=decrease from baseline of >=50% in the sum of products of the 2 largest perpendicular diameters of all index lesions.
Independent review committee performed tumor assessment.
|
Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance
|
Immune-related Best Overall Response Rate (irBORR) Per irRC in Participants With NSCLC and Small-cell Lung Cancer (SCLC)
Időkeret: Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance
|
irBORR=number of participants with irBORR of immune-related Complete Response (irCR) or immune-related Partial Response (irPR), divided by total participants in the data set.
irCR=Complete disappearance of all index lesions.
irPR=Decrease, relative to baseline, of 50% or greater in the sum of the products of the 2 largest perpendicular diameters of all index and of all new measurable lesions.
Independent review committee performed the tumor assessments.
|
Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance
|
Immune-related Disease Control Rate (irDCR) Per irRC and Disease Control Rate (DCR) Per mWHO Criteria in Participants With NSCLC and SCLC
Időkeret: Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance until irPD, progressive disease, or death (maximum reached: 22 months)
|
irDCR is defined as the proportion of participants whose immune-related best overall response is irPR, irCR, or immune-related Stable Disease (irSD) in the analysis data set.
irSD=Does not meet criteria for irCR or irPR, in the absence of progressive disease.
By mWHO criteria, DCR is defined as the proportion of participants whose best overall response is PR, CR, or SD in the analysis data set.
SD=A decrease or tumor stabilization of 1 or more nonindex lesions.
Independent review committee assessed response.
|
Tumor assessment at screening, every 6 weeks on treatment to Week 24, and every 12 weeks on maintenance until irPD, progressive disease, or death (maximum reached: 22 months)
|
Immune-related Duration of Response (irDoR) Per irRC and DoR Per mWHO Criteria in Participants With NSCLC and SCLC
Időkeret: Date of irCR or irPR to date of irPD or death (maximum reached: 14.2 months)
|
irDoR is defined as the time between the date of response of confirmed irCR or irPR and the date of irPD or death, whichever occurs first.
For those participants who remain alive and did progress following response, irDoR was censored on the date of last evaluable tumor assessment.
By mWHO criteria, DoR is defined as the time between the date of response of confirmed CR or PR and the date of PD or death, whichever occurs first.
For those who remain alive and did not progress following response, DoR was censored on the date of last evaluable tumor assessment.
|
Date of irCR or irPR to date of irPD or death (maximum reached: 14.2 months)
|
Number of Participants With NSCLC Who Have Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, and Drug-related AEs by Worst Common Terminology Criteria (CTC) Grade
Időkeret: Weeks 4, 7, 10, 16, 19, and 24; at end of treatment; and at follow-up (70 days from last dose)
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related=possibly, probably, or certainly related to and of unknown relationship to study drug.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Weeks 4, 7, 10, 16, 19, and 24; at end of treatment; and at follow-up (70 days from last dose)
|
Percentage of Participants With NSCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade
Időkeret: At screening; predose Day 1; and Weeks 4, 7, 10, 13, 16, 19, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
CTC, Version 3 used to assess parameters.
LLN=lower limit of normal.
CTC criteria: ANC=absolute neutrophil count.
White blood cells Grade (Gr) 1:<LLN to 3.0*10^9/L, Gr 2:<3.0 to 2.0*10^9/L, Gr 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L.
ANC Gr 1:<LLN to 1.5*10^9/L, Gr 2:<1.5 to 1.0*10^9/L, Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L.
Platelet count Gr 1:LLN to 75.0*10^9/L, Gr 2:<75.0 to 50.0*10^9/L, Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0 to 10^9/L.
Hemoglobin Gr 1:<LLN to 10.0 g/dL, Gr 2:<10.0 to 8.0 g/dL, Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL.
|
At screening; predose Day 1; and Weeks 4, 7, 10, 13, 16, 19, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
irPFS in Participants With SCLC Per irRC
Időkeret: Randomization date to date of irPD or death (maximum reached: 22 months)
|
IRC performed TA.
|
Randomization date to date of irPD or death (maximum reached: 22 months)
|
Number of Participants With NSCLC Who Have Abnormalities in On-Study Liver Function Test Results By Worst CTC Grade
Időkeret: At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
ULN=Upper limit of normal among all laboratory ranges.
ALT=alanine transaminase; AST=aspartate aminotransferase; ALK=alkaline phosphatase.
CTC grade criteria: ALT Grade 1:>ULN to 2.5*ULN; Grade 2: >2.5 to 5.0*ULN; Grade 3: >5.0 to 20.0*ULN; Grade 4: >20.0*ULN.
AST Grade 1: >ULN to 2.5*ULN; Grade 2: >2.5 to 5.0*ULN; Grade 3: >5.0 to 20.0*ULN; Grade 4: >20.0*ULN.
Total bilirubin Grade 1: >ULN to 1.5*ULN; Grade 2: >1.5 to 3.0*ULN; Grade 3: >3.0 to 10.0*ULN; Grade 4: >10.0*ULN.
ALK (U/L) G1:>ULN to 2.5*ULN, G2:>2.5 to 5.0*ULN, G3:>5.0 to 20.0*ULN, G4:>20.0*ULN.
|
At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
Number of Participants With NSCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings
Időkeret: At screening; Day 1; Weeks 4, 7, 10, 13, 16, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
Vital signs measurements consisted of systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.
Physical examinations assessed weight, height, performance status, and body surface area.
|
At screening; Day 1; Weeks 4, 7, 10, 13, 16, and 24; and every 12 weeks on maintenance until disease progression, study closure, or withdrawal of consent
|
Percentage of Participants With NSCLC Who Have Abnormalities in Pancreatic Enzyme Clinical Laboratory Test Results by Worst CTC Grade
Időkeret: At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
ULN=upper limit of normal.
Lipase (U/L) Gr 1: 1.1 to 1.39*ULN; Gr 2: >1.5 to 2.0*ULN; Gr 3: 2.5 to 5; Gr 4: 5*ULN.
Amylase (U/L) Gr 1: >ULN to 1.5*ULN; Grade 2 >1.5 to 2.0*ULN, Grade 3 >2.0 to 5.0*ULN, Grade 4 >5.0*ULN.
Creatine (mg/dL) Grade 1: >ULN to 1.5*ULN, Gr 2: 1.5 to 3.0*ULN, Gr 3: >3.0 to 6.0*ULN, Gr 4: >6.0*ULN.
|
At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
Number of Participants With NSCLC Who Have Positive Human Antihuman Antibody (HAHA) Status Postbaseline
Időkeret: Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
An electrochemilumiluminescent immunoassay was used to detect HAHA antibodies to ipilimumab in human serum.
Baseline, either negative or positive, is the maximum of all measurements closest and prior to the first ipilimumab dose.
Positive status postbaseline=participants with an increase in HAHA measurement from baseline.
|
Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
Number of Participants With SCLC With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs by Worst CTC Grade
Időkeret: Weeks 4, 7, 10, 16, 19, and 24; at end of treatment; and at follow-up (70 days from last dose)
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related=possibly, probably, or certainly related to and of unknown relationship to study drug.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Weeks 4, 7, 10, 16, 19, and 24; at end of treatment; and at follow-up (70 days from last dose)
|
Number of Participants With SCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade
Időkeret: At screening, predose Day 1, and Weeks 4, 7, 10, 13, 16, 19, 24, and at end of treatment
|
CTC, Version 3 used to assess parameters.
LLN=lower limit of normal.
CTC criteria: ANC=absolute neutrophil count.
White blood cells Gr 1:<LLN to 3.0*10^9/L, Gr 2:<3.0 to 2.0*10^9/L, Gr 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L.
ANC Gr 1:<LLN to 1.5*10^9/L, Gr 2:<1.5 to 1.0*10^9/L, Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L.
Platelet count Gr 1:LLN to 75.0*10^9/L, Gr 2:<75.0 to 50.0*10^9/L, Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0 to 10^9/L.
Hemoglobin Gr 1:<LLN to 10.0 g/dL, Gr 2:<10.0 to 8.0 g/dL, Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL.
|
At screening, predose Day 1, and Weeks 4, 7, 10, 13, 16, 19, 24, and at end of treatment
|
Number of Participants With SCLC Who Have Abnormalities in Liver Function Test Results by Worst CTC Grade
Időkeret: At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ALK=alkaline phosphatase.
ULN=Upper limit of normal among all laboratory ranges.
CTC grade criteria: ALT Grade 1:>ULN to 2.5*ULN; Grade 2: >2.5 to 5.0*ULN; Grade 3: >5.0 to 20.0*ULN; Grade 4: >20.0*ULN.
AST Grade 1: >ULN to 2.5*ULN; Grade 2: >2.5 to 5.0*ULN; Grade 3: >5.0 to 20.0*ULN; Grade 4: >20.0*ULN.
Total bilirubin Grade 1: >ULN to 1.5*ULN; Grade 2: >1.5 to 3.0*ULN; Grade 3: >3.0 to 10.0*ULN; Grade 4: >10.0*ULN.
ALK (U/L) G1:>ULN to 2.5*ULN, G2:>2.5 to 5.0*ULN, G3:>5.0 to 20.0*ULN, G4:>20.0*ULN.
|
At screening; predose Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
Percentage of Participants With SCLC Who Have Abnormalities in Pancreatic Enzyme and Other Clinical Laboratory Test Results by Worst CTC Grade
Időkeret: At screening, predose Day 1, and Weeks 4, 7, 10, 13, 16, 19, 24, and at end of treatment
|
ULN=upper limit of normal.
Lipase (U/L) Grade (Gr) 1: 1.1 to 1.39*ULN; Gr 2: >1.5 to 2.0*ULN; Gr 3: 2.5 to 5; Gr 4: 5*ULN.
Amylase (U/L) Gr 1: >ULN to 1.5*ULN; Gr 2 >1.5 to 2.0*ULN, Gr 3 >2.0 to 5.0*ULN, Gr 4 >5.0*ULN.
Creatine (mg/dL) Gr 1: >ULN to 1.5*ULN, Gr 2: 1.5 to 3.0*ULN, Gr 3: >3.0 to 6.0*ULN, Gr 4: >6.0*ULN.
|
At screening, predose Day 1, and Weeks 4, 7, 10, 13, 16, 19, 24, and at end of treatment
|
Progression-free Survival (PFS) in Participants With SCLC Per mWHO Criteria
Időkeret: Randomization date to date of progression or death (of censored, maximum reached: 22 months)
|
By mWHO criteria, PFS is defined as the time between the randomization date and the date of progression or death, whichever occurs first.
For participants with no recorded postbaseline tumor assessment, PFS was censored at the day of randomization.
A participant who died without reported prior progression was considered to have progressed on the date of death.
For those who remain alive and have not progressed, PFS was censored on the date of last evaluable tumor assessment.
|
Randomization date to date of progression or death (of censored, maximum reached: 22 months)
|
Number of Participants With SCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings
Időkeret: Predose Day 1; Weeks 4, 7, 10, 13, 16, and 24; and every 12 weeks on maintenance until end of treatment
|
Vital signs measurements consisted of systolic and diastolic blood pressure, heart rate, temperature, and respiratory rate.
Physical examinations assessed weight, height, performance status, and body surface area.
|
Predose Day 1; Weeks 4, 7, 10, 13, 16, and 24; and every 12 weeks on maintenance until end of treatment
|
Number of Participants With SCLC Who Have Positive HAHA Status Postbaseline
Időkeret: Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
An electrochemilumiluminescent immunoassay was used to detect HAHA antibodies to ipilimumab in human serum.
Baseline, either negative or positive, is the maximum of all measurements closest and prior to the first ipilimumab dose.
Positive status postbaseline=participants with an increase in HAHA measurement from baseline.
|
Day 1; Weeks 4, 7, 10, 13, 16, 19, and 24; and at end of treatment
|
Overall Survival in Participants With SCLC
Időkeret: Randomization date to date of death (of censored, maximum reached: 22 months)
|
Overall Survival is defined as the time from the date of randomization until the date of death.
For participants who have not died, Overall Survival was censored at the recorded last date of contact; participants with a missing recorded last date of contact were censored at the last date the participant was known to be alive.
|
Randomization date to date of death (of censored, maximum reached: 22 months)
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Szponzor
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete
2008. február 1.
Elsődleges befejezés (Tényleges)
2009. október 1.
A tanulmány befejezése (Tényleges)
2011. december 1.
Tanulmányi regisztráció dátumai
Először benyújtva
2007. szeptember 7.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2007. szeptember 10.
Első közzététel (Becslés)
2007. szeptember 11.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2018. július 18.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2018. június 18.
Utolsó ellenőrzés
2018. június 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Légúti betegségek
- Neoplazmák
- Tüdőbetegségek
- Neoplazmák webhelyenként
- Légúti neoplazmák
- Mellkasi neoplazmák
- Karcinóma, bronchogén
- Bronchiális neoplazmák
- Tüdő neoplazmák
- Karcinóma, nem kissejtes tüdő
- Kissejtes tüdőkarcinóma
- A farmakológiai hatás molekuláris mechanizmusai
- Antineoplasztikus szerek
- Tubulin modulátorok
- Antimitotikus szerek
- Mitózis modulátorok
- Daganatellenes szerek, fitogén
- Immunológiai daganatellenes szerek
- Immunellenőrzőpont-gátlók
- Carboplatin
- Paclitaxel
- Ipilimumab
Egyéb vizsgálati azonosító számok
- CA184-041
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Karcinóma, nem kissejtes tüdő
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor...Aktív, nem toborzóNon-Hodgkin limfóma | B-Cell ALL | B-sejt CLLEgyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveAnn Arbor Stage III 1. fokozatú follikuláris limfóma | Ann Arbor Stage III 2. fokozatú follikuláris limfóma | Ann Arbor III. stádiumú indolens felnőtt nem-Hodgkin limfóma | Ann Arbor IV. stádiumú, 1. fokozatú follikuláris limfóma | Ann Arbor IV. stádiumú, 2. fokozatú follikuláris limfóma | Ann... és egyéb feltételekEgyesült Államok
-
Xiangyang No.1 People's HospitalQingdao Haier Biotechnology Co.,Ltd.Még nincs toborzásRefrakter B-sejtes limfóma | B-sejtes limfóma visszatérő | NK CellKína
-
National Cancer Institute (NCI)BefejezveLimfóma | Bőr | T-CellEgyesült Államok
-
National Cancer Institute (NCI)BefejezveElsődleges mediastinalis B-sejtes limfóma | Diffúz, nagy B-sejtes limfóma | Diffúz nagy B-sejtes limfóma follikuláris limfómából átalakulva | Mantle CellEgyesült Államok
-
Merck Sharp & Dohme LLCBefejezveLimfóma, non-Hodgkin | Myeloma multiplex | Szilárd daganatok | Leukémia, limfocitás, krónikus. B-Cell
-
Assistance Publique - Hôpitaux de ParisMég nincs toborzásLimfóma, B-sejt | Myeloma multiplex | Akut limfoblasztikus leukémia | Hematológiai rosszindulatú daganat | Autó T- CellFranciaország
-
Essen BiotechMég nincs toborzásT-sejtes limfóma | T-sejtes prolimfocita leukémia | T-sejtes akut limfoblasztos leukémia | T-sejtes leukémia | A központi idegrendszer T-sejtes limfómája | T Cell Childhood ALLKína
-
National Cancer Institute (NCI)Aktív, nem toborzóLágyszöveti szarkóma | Osteosarcoma | Ewing szarkóma | Rosszindulatú glioma | Ependimoma | Rhabdoid daganat | Előrehaladott rosszindulatú szilárd daganat | Tűzálló rosszindulatú szilárd daganat | Rhabdomyosarcoma | Ismétlődő rosszindulatú szilárd daganat | Ismétlődő neuroblasztóma | Tűzálló neuroblasztóma | Tűzálló... és egyéb feltételekEgyesült Államok, Puerto Rico
-
University of Alabama at BirminghamMegszűntAnaplasztikus nagysejtes limfóma | Angioimmunoblasztos T-sejtes limfóma | Perifériás T-sejtes limfómák | Felnőttkori T-sejtes leukémia | Felnőttkori T-sejtes limfóma | Perifériás T-sejtes limfóma Meghatározatlan | T/Null Cell Systemic Type | Bőr t-sejtes limfóma csomóponti/zsigeri betegséggelEgyesült Államok
Klinikai vizsgálatok a Ipilimumab
-
Shanghai Henlius BiotechToborzás
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers SquibbIsmeretlenAgyi metasztázisokOlaszország
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical University... és más munkatársakToborzásHepatocelluláris karcinóma (HCC)Tajvan
-
Gustave Roussy, Cancer Campus, Grand ParisBefejezve
-
Ontario Clinical Oncology Group (OCOG)Bristol-Myers SquibbAktív, nem toborzóÁttétes vesesejtes karcinómaKanada, Ausztrália
-
Italian Network for Tumor BiotherapyBristol-Myers SquibbBefejezveÁttétes rosszindulatú melanomaOlaszország
-
Bristol-Myers SquibbBefejezveKarcinóma, vesesejtEgyesült Államok, Olaszország, Brazília, Argentína, Ausztrália, Ausztria, Belgium, Kanada, Chile, Kína, Colombia, Csehország, Franciaország, Németország, Japán, Mexikó, Hollandia, Lengyelország, Románia, Orosz Föderáció, Szingapúr, Spanyolorszá... és több
-
GERCOR - Multidisciplinary Oncology Cooperative...Bristol-Myers SquibbToborzásMetasztatikus vastag- és végbélrák | MSI-H vastag- és végbélrákFranciaország
-
National Cancer Institute (NCI)ToborzásGlioblasztóma | Rosszindulatú glioma | GliosarcomaEgyesült Államok
-
Italian Network for Tumor Biotherapy FoundationBristol-Myers Squibb; Astex Pharmaceuticals, Inc.Még nincs toborzásMelanóma | Nem kissejtes tüdőrákOlaszország